Completed PHASE4 INTERVENTIONAL 2-arm NCT02833688

Effects of Dexmedetomidine on the Liver Injury After Hepatectomy

the Ethnic Committee of the Chinese People's Liberation Army (PLA) General Hospital

Sponsor: Chinese PLA General Hospital

Interventions 0.9% sodium chloride dexmedetomidine

Updated 6 times since 2017 Last updated: Jan 25, 2017 Started: Aug 2, 2016 Primary completion: Jan 26, 2017 Completion: Jan 26, 2017

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT02833688, this PHASE4 trial focuses on Ischemia-reperfusion Injury and remains completed. Sponsored by Chinese PLA General Hospital, it has been updated 6 times since 2016, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE4
Jul 2024 — Sep 2024 [monthly]

Completed PHASE4
Jan 2021 — Jul 2024 [monthly]

Completed PHASE4
Jun 2018 — Jan 2021 [monthly]

Completed PHASE4
Feb 2017 — Jun 2018 [monthly]

Completed PHASE4

Status: Recruiting → Completed

▶ Show 1 earlier version

Jan 2017 — Feb 2017 [monthly]

Recruiting PHASE4

First recorded

Aug 2016

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Chinese PLA General Hospital

Data source: Chinese PLA General Hospital

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Beijing, China